Under the Paperwork Reduction Act of 1995, no persons are required to

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10738463		
Filing Date		2003-12-17		
First Named Inventor SCHL		JBERT et al.		
Art Unit		3762		
Examiner Name	Christ	lopher KOHARSKI		
Attorney Docket Number		71128		

	U.S.PATENTS						Remove			
			Name of Patentee or Applicant Relev			ges,Columns,Lines where evant Passages or Relevant ures Appear				
	1 4756706 1988-07-12 Ker		Kems et al.	Kerns et al.						
	2 5531697 1996-07-02 Olsen et al.									
	3	5531698		1996-07-	-02	Olsen				
If you wis	h to a	dd additional U.S. Pater	nt citatio	n informa	ation pl	ease click the	Add button.		Add	
			U.S.P	ATENT	APPLIC	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date		Name of Patentee or Applicant of cited Document		Releva		Lines where ges or Relevar
	1	20030088238		2003-05-08		Poulsen et al.				
	2	20060122577		2006-06	-08	Poulsen et al.				
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication	citation	n information p	please click the Ad	d button	Add	
				FOREIG	N PAT	TENT DOCUM	IENTS		Remove	
	Cite	Foreign Document	Countr	y Kind i Code4		Publication Date Name of Patentee Applicant of cited Document		eor [,	Pages,Col	umns,Lines evant T

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10738463		
Filing Date		2003-12-17		
First Named Inventor SCHL		IBERT et al.		
Art Unit		3762		
Examiner Name Christ		opher KOHARSKI		
Attorney Docket Number		71128		

	1	WO 03/026726 A1	DK		2003-04-03	Pou	ilsen et al.			
	2	WO 95/28190	US		1995-10-26	Olsa	on et al.			
If you wisi	h to a	dd additional Foreigr	n Patent Document	citation	information p	lease	click the Add butto	n Add		
			NON-PATE	NT LITE	RATURE DO	CUM	IENTS	Remove		
Examiner Initials*	Examiner Cite include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.							Тs		
	1									
If you wis	h to a	dd additional non-pa	tent literature docu	ment ci	tation informat	tion p	lease click the Add	button Add		
EXAMINER SIGNATURE										
Examiner	Examiner Signature Date Considered									
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.										

See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WiPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the right of the Emperor must precede the senial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbole as indicated on the document under WIPO Standard ST.16 if possible. <sup>3</sup> Applicant is to pleas a check mark here if

English language translation is attached.

### INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10738463
Filing Date		2003-12-17
First Named Inventor	SCHL	JBERT et al.
Art Unit		3762
Examiner Name	Christ	opher KOHARSKI
Attorney Docket Number		71128

#### CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

	That each item of information contained in the information disclosure statement was first cited in any communication
$\times$	from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the

OR

That no item of information contained in the information disclosure statement, was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ▼ None

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/john james moglew/	Date (YYYY-MM-DD)	2007-05-04				
Manage / Dalant	John James McClaus	Decistostica Number	24002				

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary Cfing. U.S. Operatment of Commence, P. 0. Box 1450, Alexandria, V.S. 2313-1450. D. ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2313-1450.

### Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
  application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
  disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
  which became abandoned or in which the proceedings were terminated and which application is referenced by either a
  published application, an application open to public inspections or as issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.